Andrew Kirby1, Ibrahim Hassan, James Burnie. 1. Department of Microbiology, Clinical Sciences Building, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. kirbyandrew@doctors.org.uk
Abstract
OBJECTIVES: To produce recommendations for the management of Aspergillus osteomyelitis and joint infections. METHODS: Published literature was surveyed to identify both case reports of Aspergillus osteomyelitis and joint infections and anti-fungal pharmacology of anti-fungal agents. Included in the pharmacological review was an assessment of new and investigational anti-fungals to consider their potential role in the management of this infection. RESULTS: Successful treatments, identified from the cases reviewed, were based on combination anti-fungal therapy with one agent having good bone penetration and one having reliable anti-Aspergillus activity. CONCLUSIONS: For the management of serious Aspergillus osteomyleitis/joint infections amphotericin B in combination with flucytosine is recommended. A number of second line treatment combinations are identified. Monotherapy is appropriate with an azole in clinically stable patients.
OBJECTIVES: To produce recommendations for the management of Aspergillus osteomyelitis and joint infections. METHODS: Published literature was surveyed to identify both case reports of Aspergillus osteomyelitis and joint infections and anti-fungal pharmacology of anti-fungal agents. Included in the pharmacological review was an assessment of new and investigational anti-fungals to consider their potential role in the management of this infection. RESULTS: Successful treatments, identified from the cases reviewed, were based on combination anti-fungal therapy with one agent having good bone penetration and one having reliable anti-Aspergillus activity. CONCLUSIONS: For the management of serious Aspergillus osteomyleitis/joint infectionsamphotericin B in combination with flucytosine is recommended. A number of second line treatment combinations are identified. Monotherapy is appropriate with an azole in clinically stable patients.
Authors: D Neofytos; S Huprikar; A Reboli; M Schuster; N Azie; B Franks; D Horn Journal: Eur J Clin Microbiol Infect Dis Date: 2013-08-02 Impact factor: 3.267
Authors: Paul E Verweij; Debbie T A Te Dorsthorst; Willem H P Janssen; Jacques F G M Meis; Johan W Mouton Journal: Antimicrob Agents Chemother Date: 2008-09-15 Impact factor: 5.191
Authors: Gregory L Hall; Esperanza Villanueva-Siles; Ross M Borzykowski; Konrad I Gruson; Howard D Dorfman; David S Geller Journal: Skeletal Radiol Date: 2012-03-31 Impact factor: 2.199
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079